突变肽对MHC-I的差异结合亲和力可预测晚期肺癌和黑色素瘤生存
研究利用癌症基因组图谱中晚期非小细胞肺癌(LUAD,n=66)和黑色素瘤(SKCM,n=72)队列,以及免疫治疗队列(黑色素瘤n=131,NSCLC n=31),分析突变肽与野生型肽对MHC-I预测结合亲和力的差异(DAI)与免疫浸润及生存的关系。结果显示平均DAI在3/5队列中与总生存显著相关,且优于突变负荷和新抗原负荷,并与免疫浸润标志物正相关。
要点
- 平均DAI在部分队列中与晚期肺癌和黑色素瘤患者总生存相关
- DAI对生存的预测优于非 synonymous 突变负荷和新抗原负荷
- DAI与免疫浸润标志物正相关,支持其反映肽免疫原性
核心结论
- 平均DAI与生存及免疫活性指标相关,支持DAI是癌症肽免疫原性的决定因素。
研究设计与样本
- 回顾性分析癌症基因组图谱中晚期NSCLC(LUAD,n=66)和黑色素瘤(SKCM,n=72)队列。
- 另分析免疫治疗治疗的晚期黑色素瘤(总n=131)和NSCLC(n=31)队列。
- 利用基因组数据定义新抗原肽及其克隆状态,预测MHC-I结合亲和力并计算样本平均DAI。
主要发现
- 单变量和多变量分析中,平均DAI在3/5队列中与总生存显著相关。
- 在这些队列中,平均DAI的效应见于克隆性肽而非亚克隆性肽。
- SKCM中平均DAI与生存的关联接近显著性(P=0.068),在免疫治疗黑色素瘤队列中达到显著(P=0.003)。
- 平均DAI(而非突变负荷或新抗原负荷)与免疫浸润标志物在SKCM(P=0.027)和LUAD(P=0.024)中正相关。
临床怎么用
- DAI有望作为免疫相关肽的标志物,用于新抗原免疫治疗的进一步临床研究。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer mutations generate novel (neo-)peptides recognised by T cells, but the determinants of recognition are not well characterised. The difference in predicted class I major histocompatibility complex (MHC-I) binding affinity between wild-type and corresponding mutant peptides (differential agretopicity index; DAI) may reflect clinically relevant cancer peptide immunogenicity. Our aim was to explore the relationship between DAI, measures of immune infiltration and patient outcomes in advanced cancer. PATIENTS AND METHODS: Cohorts of patients with advanced non-small-cell lung cancer (NSCLC; LUAD, n = 66) and melanoma (SKCM, n = 72) were obtained from The Cancer Genome Atlas. Three additional cohorts of immunotherapy treated patients with advanced melanoma (total n = 131) and NSCLC (n = 31) were analysed. Neopeptides and their clonal status were defined using genomic data. MHC-I binding affinity was predicted for each neopeptide and DAI values summarised as the sample mean DAI. Correlations between mean DAI and markers of immune activity were evaluated using measures of lymphocyte infiltration and immune gene expression. RESULTS: In univariate and multivariate analyses, mean DAI significantly correlated with overall survival in 3/5 cohorts, with evidence of superiority over nonsynonymous mutational and neoantigen burden. In these cohorts, the effect was seen for mean DAI of clonal but not subclonal peptides. In SKCM, the association between mean DAI and survival bordered significance (P = 0.068), reaching significance in an immunotherapy-treated melanoma cohort (P = 0.003). Mean DAI but not mutational nor neoantigen burden was positively correlated with independently derived markers of immune infiltration in both SKCM (P = 0.027) and LUAD (P = 0.024). CONCLUSIONS: The association between mean DAI, survival and measures of immune activity support the hypothesis that DAI is a determinant of cancer peptide immunogenicity. Investigation of DAI as a marker of immunologically relevant peptides in further datasets and future clinical studies of neoantigen based immunotherapies is warranted.
引用
- Ghorani E, Rosenthal R, McGranahan N, et al. Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma. Ann Oncol. 2018. PMID: 29361136. doi:10.1093/annonc/mdx687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。